Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

Articles

A positive association was found between osteoarthritis and overactive bladder (OAB), but rheumatoid arthritis and psoriatic arthritis were not significantly correlated with the condition.

Findings Suggest Potential Link Between Overactive Bladder, Osteoarthritis

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable treatment option for patients.

Bimekizumab for Hidradenitis Suppurativa Offers Durable Disease Control in Long-Term Data

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial. 

Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

The large UK Biobank study finds depression a significant risk predictor for developing chronic conditions such as osteoarthritis, hypertension, and gastro-oesophageal reflux disease.

Adults With Depression Likely Develop Physical Conditions 30% Faster

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Advancing CLL and MCL Care: The Impact of BTK Inhibitors in Treatment-Naive Patients and Emerging Therapies

Video Series

Therapy Sequencing in CLL

How do you sequence therapies for patients with CLL, and how does prior therapy exposure influence your subsequent choice of treatments?

Videos

Panelists discuss how emerging Bruton tyrosine kinase (BTK) inhibitors and combination regimens are addressing unmet needs in the treatment of chronic lymphocytic leukemia(CLL) and mantle cell lymphoma (MCL), with a focus on improving outcomes for treatment-naive patients and advancing current therapeutic strategies.

Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for treatment-naive patients, with a focus on emerging Bruton tyrosine kinase inhibitor (BTKi) regimens such as acalabrutinib plus venetoclax, pirtobrutinib plus venetoclax, and zanubrutinib combinations.

Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi) trials in chronic lymphocytic leukemia (CLL) are addressing unmet needs by offering new treatment options that target treatment-naive patients, potentially improving outcomes and filling gaps in the current therapeutic landscape.

Clinical Implications and Unmet Needs in CLL BTKi Therapies

Panelists discuss how emerging  Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.

Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL)  and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.

Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) may include issues related to access, cost, and patient adherence, and highlight the need for ongoing research and collaboration to optimize BTKi use and improve patient outcomes in both diseases.

Future Directions and Research Priorities in BTKi Treatment Approaches

Latest Trends and Innovations in CLL and MCL Treatment 

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and explore the continued role of ibrutinib in the CLL treatment landscape.

CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors 

Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.

Navigating CLL Treatment Choices

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on how prior therapy exposure influences the choice of subsequent treatments.

Therapy Sequencing in CLL

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 8.Navigating CLL Treatment Choices

EP: 9.Therapy Sequencing in CLL